PROTHENA CORP PUBLIC LTD CO
PRTANext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for PRTA. That does not mean none is planned.
Get an email about PRTA's next catalysts
Track PROTHENA CORP PUBLIC LTD CO (PRTA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Prasinezumab | Phase 3 | Parkinson's Disease | - | - |
NEOD001 | Phase 2 | Primary Amyloidosis | - | - |
Frequently asked questions
What is in PROTHENA CORP PUBLIC LTD CO's drug pipeline?→
CatalystAlert tracks 2 drug candidates in PROTHENA CORP PUBLIC LTD CO's (PRTA) pipeline across Phase 3, Phase 2. Its lead program is Prasinezumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PROTHENA CORP PUBLIC LTD CO's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for PROTHENA CORP PUBLIC LTD CO (PRTA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track PRTA biotech catalysts?→
Add PRTA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PROTHENA CORP PUBLIC LTD CO's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.